Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BELLUS Health Inc BLUSD


Primary Symbol: T.BLU

Healthcare Biotechnology
BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.


TSX:BLU - Post by User

BELLUS Health Inc > RBC $ 80.00 Target on BLU should be $ 8.00 ......
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(17)
•••
Post by blueblackon Jan 30, 2021 10:01am
356 Views
Post# 32427917

RBC $ 80.00 Target on BLU should be $ 8.00 ......

RBC $ 80.00 Target on BLU should be $ 8.00 ......You would think that RBC would have corrected this ; I am sure they know. All these guys are so F#!*!* dishonest.

Very sad !!!

BTW I personally think it will go higher than $ 8.00 but unfortunately not $ 80.00.

Keeping IT REAL !!!

B.B.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities